Stay updated on TNT Clinical Trial: Talimogene + Nivolumab + Trabectedin

Sign up to get notified when there's something new on the TNT Clinical Trial: Talimogene + Nivolumab + Trabectedin page.
Latest website image capture
Clouds background image

Latest updates to the TNT Clinical Trial: Talimogene + Nivolumab + Trabectedin page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    An NIH-wide banner announces a terminology change from “AI” to “SI,” and the site revision advances from v3.7.1 to v3.7.2. The study page still shows a 403 Forbidden error.
    Difference
    1%
    Check dated 2026-10-21T00:41:24.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov revision identifier changes from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-07T00:50:01.000Z thumbnail image
  5. Check
    38 days ago
    Change Detected
    Summary
    The study record page now displays a 403 Forbidden error, blocking access to its content. Users can no longer view the study details, eligibility criteria, contacts, or locations from that page.
    Difference
    19%
    Check dated 2026-09-23T00:42:47.000Z thumbnail image
  6. Check
    45 days ago
    Change Detected
    Summary
    The contact information label was standardized from 'Find Contact Information' to 'Find contact information', and the page revision tag was updated from v3.6.6 to v3.7.0, signaling a small UI/text update and version bump.
    Difference
    0.1%
    Check dated 2026-09-16T00:08:46.000Z thumbnail image
  7. Check
    59 days ago
    Change Detected
    Summary
    The page revision was updated from v3.6.5 to v3.6.6. This indicates a new version of the page has been published.
    Difference
    0.2%
    Check dated 2026-09-01T19:40:57.000Z thumbnail image
  8. Check
    66 days ago
    Change Detected
    Summary
    No textual changes are documented in the provided data; the page content remains as described in the current study record. The study details, including design, endpoints, and eligibility criteria, remain centered on the TNT trial and its locations.
    Difference
    0.1%
    Check dated 2026-08-25T19:20:33.000Z thumbnail image

Stay in the know with updates to TNT Clinical Trial: Talimogene + Nivolumab + Trabectedin

Enter your email address, and we'll notify you when there's something new on the TNT Clinical Trial: Talimogene + Nivolumab + Trabectedin page.